Cargando…
Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
Primary liver cancer (PLC) is one of the most common solid malignancies. However, PLC drug development has been slow, and first-line treatments are still needed; thus, studies exploring and developing alternative strategies for effective PLC treatment are urgently needed. Chinese herbal medicine (CH...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117702/ https://www.ncbi.nlm.nih.gov/pubmed/35600861 http://dx.doi.org/10.3389/fphar.2022.889799 |
_version_ | 1784710367741476864 |
---|---|
author | Li, Kexin Xiao, Kunmin Zhu, Shijie Wang, Yong Wang, Wei |
author_facet | Li, Kexin Xiao, Kunmin Zhu, Shijie Wang, Yong Wang, Wei |
author_sort | Li, Kexin |
collection | PubMed |
description | Primary liver cancer (PLC) is one of the most common solid malignancies. However, PLC drug development has been slow, and first-line treatments are still needed; thus, studies exploring and developing alternative strategies for effective PLC treatment are urgently needed. Chinese herbal medicine (CHM) has long been applied in the clinic due to its advantages of low toxicity and targeting of multiple factors and pathways, and it has great potential for the development of novel natural drugs against PLC. Purpose: This review aims to provide an update on the pharmacological mechanisms of Chinese patent medicines (CPMs) and the latest CHM-derived compounds for the treatment of PLC and relevant clinical evaluations. Materials and Methods: A systematic search of English literature databases, Chinese literature, the Clinical Trials Registry Platform, and the Chinese Clinical Trial Registry for studies of CHMs for PLC treatment was performed. Results: In this review, we summarize the clinical trials and mechanisms of CPMs for PLC treatment that have entered the clinic with the approval of the Chinese medicine regulatory authority. These CPMs included Huaier granules, Ganfule granules, Fufang Banmao capsules, Jinlong capsules, Brucea javanica oil emulsions, and compound kushen injections. We also summarize the latest in vivo, in vitro, and clinical studies of CHM-derived compounds against PLC: icaritin and ginsenoside Rg3. Dilemmas facing the development of CHMs, such as drug toxicity and low oral availability, and future developments are also discussed. Conclusion: This review provides a deeper the understanding of CHMs as PLC treatments and provides ideas for the development of new natural drugs against PLC. |
format | Online Article Text |
id | pubmed-9117702 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91177022022-05-20 Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges Li, Kexin Xiao, Kunmin Zhu, Shijie Wang, Yong Wang, Wei Front Pharmacol Pharmacology Primary liver cancer (PLC) is one of the most common solid malignancies. However, PLC drug development has been slow, and first-line treatments are still needed; thus, studies exploring and developing alternative strategies for effective PLC treatment are urgently needed. Chinese herbal medicine (CHM) has long been applied in the clinic due to its advantages of low toxicity and targeting of multiple factors and pathways, and it has great potential for the development of novel natural drugs against PLC. Purpose: This review aims to provide an update on the pharmacological mechanisms of Chinese patent medicines (CPMs) and the latest CHM-derived compounds for the treatment of PLC and relevant clinical evaluations. Materials and Methods: A systematic search of English literature databases, Chinese literature, the Clinical Trials Registry Platform, and the Chinese Clinical Trial Registry for studies of CHMs for PLC treatment was performed. Results: In this review, we summarize the clinical trials and mechanisms of CPMs for PLC treatment that have entered the clinic with the approval of the Chinese medicine regulatory authority. These CPMs included Huaier granules, Ganfule granules, Fufang Banmao capsules, Jinlong capsules, Brucea javanica oil emulsions, and compound kushen injections. We also summarize the latest in vivo, in vitro, and clinical studies of CHM-derived compounds against PLC: icaritin and ginsenoside Rg3. Dilemmas facing the development of CHMs, such as drug toxicity and low oral availability, and future developments are also discussed. Conclusion: This review provides a deeper the understanding of CHMs as PLC treatments and provides ideas for the development of new natural drugs against PLC. Frontiers Media S.A. 2022-05-05 /pmc/articles/PMC9117702/ /pubmed/35600861 http://dx.doi.org/10.3389/fphar.2022.889799 Text en Copyright © 2022 Li, Xiao, Zhu, Wang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Kexin Xiao, Kunmin Zhu, Shijie Wang, Yong Wang, Wei Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges |
title | Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges |
title_full | Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges |
title_fullStr | Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges |
title_full_unstemmed | Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges |
title_short | Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges |
title_sort | chinese herbal medicine for primary liver cancer therapy: perspectives and challenges |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117702/ https://www.ncbi.nlm.nih.gov/pubmed/35600861 http://dx.doi.org/10.3389/fphar.2022.889799 |
work_keys_str_mv | AT likexin chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges AT xiaokunmin chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges AT zhushijie chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges AT wangyong chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges AT wangwei chineseherbalmedicineforprimarylivercancertherapyperspectivesandchallenges |